Detection of complement-dependent antibody to tumor cells in sera of strain-2 guinea pigs cured of their tumors by BCG Treatment.
Sera of strain-2 guinea pigs (cured of line-10 tumor by BCG therapy) were tested for complement-dependent, cytotoxic antibody. About 30% of the sera tested contained significant cytotoxic acitivity with the addition of human, but not syngeneic, complement. Using papain pretreated line-10 cells, we detected antibody in about 50% of the sera with syngeneic sera as the source of complement. Antibody to line-10 was also demonstrated in selected sera by indirect fluorescence and the C1 fixation and transfer test.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis; D001500:BCG Vaccine; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy; D003168:Complement Fixation Tests; D003601:Cytotoxicity Tests, Immunologic; D005455:Fluorescent Antibody Technique; D006168:Guinea Pigs; D007167:Immunotherapy; D008113:Liver Neoplasms; D009163:Mycobacterium bovis / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy
D000912:Antibodies, Neoplasm; D001500:BCG Vaccine